Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Erwin Daniel Brenndörfer, Anette Brass, Lars Frelin, Matti Sällberg, Soo Aleman, Johannes G. Bode, Jonas Söderholm
Publikováno v:
Gut. 61:589-596
Background The non-structural (NS) 3/4A protease/helicase of the hepatitis C virus is known to modulate signalling pathways in the infected hepatocyte by cleaving CARD adaptor inducing IFNβ (Cardif), T-cell protein tyrosine phosphatase (TC-PTP) and
Autor:
Ingrid Laurendeau, Audrey Sabbagh, Ivan Bièche, Dominique Valla, Marie-Pierre Ripault, Michèle Martinot-Peignoux, Stéphanie Narguet, Patrick Marcellin, Nathalie Boyer, Michel Vidaud, Tarik Asselah
Publikováno v:
Gut. 57:516-524
Background and Aims The gold standard treatment of chronic hepatitis C is the combination of pegylated interferon plus ribavirin. Considering side effects and treatment cost, prediction of treatment response before therapy is important. The aim of ou
Autor:
D. Renda, Marcello Capra, O. Lo Iacono, S. Grutta, Aurelio Maggio, V. Di Marco, C. Ciaccio, Calogera Gerardi, P.L. Almasio, R. Pisa
Publikováno v:
Gut. 34
In this open, pilot study, interferon (IFN) alpha-2b seemed effective in the treatment of hepatitis C virus (HCV) infection in patients with beta-thalassaemia. In seven of nine patients who completed the study alanine aminotransferase activities retu
Publikováno v:
Gut. 34
In a study of 60 patients with non-A, non-B/type C (NANB/C) chronic hepatitis alanine aminotransferase (ALT) activities returned to normal after treatment with interferon alfa-2b (3 million units for six months) in 70.7% and 29.3% did not respond. Th
Publikováno v:
Gut. 34
In a study of 37 patients with hepatitis C (proved histologically) positive chronic hepatitis, a correlation was seen between clinical efficacy and histological improvement after treatment with interferon alfa-2b (3 million units (MU) three times a w